Cefaclor

ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Cefaclor is an ofp drug catalogued in DrugCentral. It was first approved by the FDA in 1979. DrugCentral lists 3 molecular targets, including ska, pbpA and mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB. Recorded indications include Acute bacterial bronchitis, Acute Moraxella catarrhalis bronchitis, Haemophilus Influenzae Bronchitis and Haemophilus Influenzae Chronic Bronchitis.

• Approval status: ofp (first approved 1979 by the FDA).
• Molecular targets: ska, pbpA and mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB (3 listed in DrugCentral).
• Indications: Acute bacterial bronchitis, Acute Moraxella catarrhalis bronchitis, Haemophilus Influenzae Bronchitis, Haemophilus Influenzae Chronic Bronchitis and Haemophilus influenzae pneumonia and others.
• ATC code: J01DC04 (Second-generation cephalosporins).
• Molecular formula: C15H14ClN3O4S; molecular weight 367.80 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (20)

• Acute bacterial bronchitis
• Acute Moraxella catarrhalis bronchitis
• Haemophilus Influenzae Bronchitis
• Haemophilus Influenzae Chronic Bronchitis
• Haemophilus influenzae pneumonia
• Infection due to Staphylococcus aureus
• Infection of skin AND/OR subcutaneous tissue
• Infective otitis media
• Lower respiratory tract infection
• Moraxella Catarrhalis Chronic Bronchitis
• Pharyngitis
• Pneumonia
• Pneumonia due to Streptococcus
• Streptococcal tonsillitis
• Streptococcus Pneumoniae Bronchitis
• Streptococcus Pneumoniae Chronic Bronchitis
• Streptococcus pyogenes infection
• Tonsillitis
• Upper respiratory infection
• Urinary tract infectious disease

Off-label uses (1)

• Pyrexia of unknown origin

Contraindications (1)

• Pseudomembranous enterocolitis

Mechanism & targets

Molecular targets (3)

Target	Gene	Action	Activity
Streptokinase A	ska	unknown	EC50 6.33
Penicillin-binding protein 1A	pbpA	unknown	—
Bacterial penicillin-binding protein	mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB	inhibitor	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1979-04-04	FDA	—	—

ATC classification

ATC code	Therapeutic hierarchy
J01DC04	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › OTHER BETA-LACTAM ANTIBACTERIALS › Second-generation cephalosporins

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Drug hypersensitivity	824.9
International normalised ratio fluctuation	727.8
Bloody discharge	490.7
Cross sensitivity reaction	489.3
Type IV hypersensitivity reaction	482.1
Lyme disease	426.1
Therapeutic product effect incomplete	192.1
Rash maculo-papular	153.9
Iron deficiency	151.2
Platelet count increased	139.1
Infection	130.5
Secretion discharge	123.4

Chemical structure

• Molecular formula: C₁₅H₁₄ClN₃O₄S
• Molecular weight: 367.80 g/mol
• CAS number: 53994-73-3
• InChIKey: QYIYFLOTGYLRGG-GPCCPHFNSA-N
• PubChem CID: 51039

N[C@@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)C1=CC=CC=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Cefaclor used for?

DrugCentral lists the following indications for Cefaclor: Acute bacterial bronchitis, Acute Moraxella catarrhalis bronchitis, Haemophilus Influenzae Bronchitis, Haemophilus Influenzae Chronic Bronchitis, Haemophilus influenzae pneumonia, Infection due to Staphylococcus aureus, Infection of skin AND/OR subcutaneous tissue and Infective otitis media and others.

How does Cefaclor work?

Its molecular targets in DrugCentral include ska, pbpA and mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB (inhibitor).

When was Cefaclor first approved?

Cefaclor was first approved by the FDA in 1979.

What is the chemical formula of Cefaclor?

Cefaclor has the molecular formula C15H14ClN3O4S and a molecular weight of 367.80 g/mol.

Sources

• DrugCentral drug card 525 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201018 — compound record and bioactivity
• PubChem CID 51039 — chemical identifiers
• DrugBank DB00833 — drug record
• FDA UNII 69K7K19H4L — substance identity
• DailyMed: FDA labels for Cefaclor — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.